Felicia Hill-Briggs, PhD, states that adherence and quality of life outcomes are equally important as comparative effectiveness research in clinical trials.
In this video, Felicia Hill-Briggs, PhD, discusses how adherence and quality-of-life outcomes are equally important in overall treatment effectiveness data for clinical trials, as it is important to distinguish whether negative treatment effectiveness data are indicative of the performance of the drug itself or poor adherence by the participant. In addition, it’s important to track medication adherence during clinical trials, so that these data can be considered as part of the treatment’s overall effectiveness or ineffectiveness during the review process.
Dr. Hill-Briggs also notes that quality-of-life data are important because it determines whether a patient will continue or maintain a treatment. “Patients have to manage their diseases and medical conditions, particularly diabetes, in the context of living a life and for a lifetime,” says Dr. Hill-Briggs.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More